Coloplast down 4% as UBS sees limited upside after guidance cut

Coloplast's shares fell over 4% following UBS's downgrade of the company from a "buy" to a "neutral" rating. The broker cited limited upside potential due to Coloplast's current valuation, which the firm considers justified but has little room for further growth. UBS adjusted its medium-term growth and margin targets, stating that Coloplast trades at a 20% premium to the broader medical technology sector, consistent with slightly lower expected growth.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.